134 related articles for article (PubMed ID: 7353378)
1. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
[No Abstract] [Full Text] [Related]
2. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
Malluche HH; Goldstein DA; Massry SG
Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
[No Abstract] [Full Text] [Related]
3. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
von Herrath D; Kraft D; Schaefer K; Krempien B
MMW Munch Med Wochenschr; 1974 Sep; 116(37):1573-8. PubMed ID: 4374654
[No Abstract] [Full Text] [Related]
4. A skeletal mineralizing defect in dialysis patients: a syndrome resembling osteomalacia but unrelated to viatamin D.
Coburn JW; Sherrard DJ; Brickman AS; Wong EG; Norman AW; Singer FR
Contrib Nephrol; 1980; 18():172-83. PubMed ID: 7353374
[No Abstract] [Full Text] [Related]
5. Do parathyroid hormone and 1,25-dithydroxyvitamin D modulate bone formation in uremia?
Teitelbaum SL; Bergfeld MA; Freitag J; Hruska KA; Slatopolsky E
J Clin Endocrinol Metab; 1980 Aug; 51(2):247-51. PubMed ID: 6893204
[No Abstract] [Full Text] [Related]
6. Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure.
Sherrard DJ; Coburn JW; Brickman AS; Singer FR; Maloney N
Contrib Nephrol; 1980; 18():92-7. PubMed ID: 7353382
[No Abstract] [Full Text] [Related]
7. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
Voigts AL; Felsenfeld AJ; Llach F
Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
[TBL] [Abstract][Full Text] [Related]
8. Uremic osteodystrophy. The therapeutic consequences of effective control of serum phosphorus.
Pinggera WF; Popovtzer MM
JAMA; 1972 Dec; 222(13):1640-2. PubMed ID: 4678366
[No Abstract] [Full Text] [Related]
9. Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients.
Goldstein DA; Malluche HH; Massry SG
Contrib Nephrol; 1980; 18():42-54. PubMed ID: 7353379
[No Abstract] [Full Text] [Related]
10. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease.
Kanis JA; Russell RG; Cundy T; Earnshaw M; Woods CG; Smith R; Heynen G
Contrib Nephrol; 1980; 18():12-28. PubMed ID: 7353370
[TBL] [Abstract][Full Text] [Related]
12. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
[TBL] [Abstract][Full Text] [Related]
13. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
[TBL] [Abstract][Full Text] [Related]
14. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3.
Pierides AM; Skillen AW; Ellis HA
J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
[TBL] [Abstract][Full Text] [Related]
16. Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.
Teitelbaum SL
Ann Intern Med; 1981 Mar; 94(3):404-5. PubMed ID: 6894359
[No Abstract] [Full Text] [Related]
17. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
[No Abstract] [Full Text] [Related]
18. Short-term effects of vitamin D3 and 1,25-dihydroxyvitamin D3 on osteomalacia in uremic rats fed a low calcium-low-phosphorus diet.
Weisbrode SE
Am J Pathol; 1981 Jul; 104(1):35-40. PubMed ID: 6266257
[TBL] [Abstract][Full Text] [Related]
19. 'One-alpha'.
Lancet; 1978 May; 1(8071):973-4. PubMed ID: 76898
[No Abstract] [Full Text] [Related]
20. Evidence that different vitamin D sterols have qualitatively different effects in man.
Rasmussen H; Bordier P
Contrib Nephrol; 1980; 18():184-91. PubMed ID: 7353375
[No Abstract] [Full Text] [Related]
[Next] [New Search]
